Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    IMUC

Delayed Quote. Delayed  - 08/30 10:02:01 pm
0.1261 USD   +2.11%
08/22 IMMUNOCELLULAR : Announces Second Quarter 2016 Financial Results
08/17 IMMUNOCELLULAR : to Report Second Quarter 2016 Financial Results on..
08/09 IMMUNOCELLULAR : Announces Pricing of $7.4 Million Public Offering
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
08/24/2016 08/25/2016 08/26/2016 08/29/2016 08/30/2016 Date
0.1255(c) 0.1202(c) 0.1195(c) 0.1235(c) 0.1261 Last
3 158 654 3 782 487 3 275 156 2 919 597 4 392 865 Volume
-1.95% -4.22% -0.58% +3.35% +2.11% Change
More quotes
Financials ($)
Sales 2016 0,75 M
EBIT 2016 -22,5 M
Net income 2016 -23,0 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,15 M
EBIT 2017 -23,5 M
Net income 2017 -24,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 21,1x
Capi. / Sales2017 7,35x
Capitalization 15,8 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers.ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
08/22 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
08/22 IMMUNOCELLULAR THERAPEUTICS : Management's Discussion and Analysis of Financial ..
08/22 IMMUNOCELLULAR THERAPEUTICS : Announces Second Quarter 2016 Financial Results
08/18 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of $7.4 Million Public Offering
08/17 IMMUNOCELLULAR THERAPEUTICS : to Report Second Quarter 2016 Financial Results on..
08/09 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of $7.4 Million Public Offering
08/04 IMMUNOCELLULAR THERAPEUTICS : Reports Progress in Two Lead Cancer Immunotherapy ..
07/25 IMMUNOCELLULAR THERAPEUTICS : Reports Progress in Two Lead Cancer Immunotherapy ..
06/21 IMMUNOCELLULAR THERAPEUTICS, LTD. : Submission of Matters to a Vote of Security ..
06/16 IMMUNOCELLULAR THERAPEUTICS : Treats First Patient in ICT-107 Phase 3 Registrati..
More news
Sector news : Biotechnology & Medical Research - NEC
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/22 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
08/22 ImmunoCellular Therapeutics beats by $0.01
06/07 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
05/12 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q1 2016 Results - Ea..
05/12 ImmunoCellular Therapeutics beats by $0.01
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | IMUC | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1,35 $
Spread / Average Target 993%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Gengos President, Chief Executive Officer & Director
Gary S. Titus Chairman
David E. Fractor Principal Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Secretary & Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..-66.37%16
INCYTE CORPORATION-25.01%15 290
CELLTRION, INC.--.--%11 038
LONZA GROUP AG14.78%10 080
QUINTILES TRANSNATIONA..12.76%9 173
ALKERMES PLC-43.98%6 740
More Results